EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma

Hong Jun Lee iD, Jae Seung Lee iD, Hyesung So iD, Ja Kyung Yoon iD, Jin-Young Choi iD, Hye Won Lee iD, Beom Kyung Kim iD, Seung Up Kim iD, Jun Yong Park iD, Sang Hoon Ahn iD, Do Young Kim iD

Yonsei Medical Journal · 2024

DOI: 10.3349/ymj.2023.0263 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Yonsei Medical Journal, 2024. Verfasst von Hong Jun Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Hepatocellular, Phenylurea Compounds, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, HepatocellularPhenylurea CompoundsPyridinesSorafenibLiver NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultProgression-Free Survival

Stichwörter der Autor:innen

Carcinoma, hepatocellularangiogenesis inhibitorsantineoplastic agents, immunologicalimmune checkpoint inhibitorsnivolumabregorafenib

Substanzen

regorafenibNivolumabPhenylurea CompoundsPyridinesSorafenib

Autor:innen und Institutionen

  • Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
  • Yonsei Liver Center, Severance Hospital, Seoul, Korea.
  • Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Yonsei Liver Center, Severance Hospital, Seoul, Korea. dyk1025@yuhs.ac.

ORCID-Profile: Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim

Zitieren

APA

Lee, H. J., Lee, J. S., So, H., Yoon, J. K., Choi, J. Y., Lee, H. W., Kim, B. K., Kim, S. U., Park, J. Y., Ahn, S. H., & Kim, D. Y. (2024). Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2023.0263

Vancouver

Lee HJ, Lee JS, So H, Yoon JK, Choi JY, Lee HW, et al. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma. Yonsei Medical Journal. 2024. doi:10.3349/ymj.2023.0263

BibTeX
@article{Lee2024,
  author = {Lee, Hong Jun and Lee, Jae Seung and So, Hyesung and Yoon, Ja Kyung and Choi, Jin-Young and Lee, Hye Won and Kim, Beom Kyung and Kim, Seung Up and Park, Jun Yong and Ahn, Sang Hoon and Kim, Do Young},
  title = {Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma},
  journal = {Yonsei Medical Journal},
  year = {2024},
  doi = {10.3349/ymj.2023.0263}
}
Kostenlos starten →